DE60024360D1 - Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS) - Google Patents
Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS)Info
- Publication number
- DE60024360D1 DE60024360D1 DE60024360T DE60024360T DE60024360D1 DE 60024360 D1 DE60024360 D1 DE 60024360D1 DE 60024360 T DE60024360 T DE 60024360T DE 60024360 T DE60024360 T DE 60024360T DE 60024360 D1 DE60024360 D1 DE 60024360D1
- Authority
- DE
- Germany
- Prior art keywords
- nervous system
- central nervous
- cns
- compositions
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13742199P | 1999-06-04 | 1999-06-04 | |
US137421P | 1999-06-04 | ||
US15105099P | 1999-08-27 | 1999-08-27 | |
US151050P | 1999-08-27 | ||
US16768199P | 1999-11-29 | 1999-11-29 | |
US167681P | 1999-11-29 | ||
US17460700P | 2000-01-05 | 2000-01-05 | |
US174607P | 2000-01-05 | ||
US18220000P | 2000-02-14 | 2000-02-14 | |
US182200P | 2000-02-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60024360D1 true DE60024360D1 (de) | 2006-01-05 |
DE60024360T2 DE60024360T2 (de) | 2006-06-08 |
Family
ID=27538049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60024360T Expired - Lifetime DE60024360T2 (de) | 1999-06-04 | 2000-06-05 | Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS) |
Country Status (7)
Country | Link |
---|---|
US (4) | US6479481B1 (de) |
EP (2) | EP1595543B1 (de) |
JP (2) | JP2001010976A (de) |
AT (1) | ATE311179T1 (de) |
CA (1) | CA2310534C (de) |
DE (1) | DE60024360T2 (de) |
ES (2) | ES2251939T3 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
US6479481B1 (en) | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US7151099B2 (en) | 1998-07-31 | 2006-12-19 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases |
US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
US20070275955A1 (en) * | 1997-07-31 | 2007-11-29 | Ed. Geistlich Soehne Ag | Method of treating tumors |
US20050096314A1 (en) * | 2001-04-03 | 2005-05-05 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US6821968B2 (en) * | 2001-09-26 | 2004-11-23 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Stable taurolidine electrolyte solutions |
US20020098164A1 (en) * | 2000-10-27 | 2002-07-25 | Redmond H. Paul | Treatment of tumor metastases and cancer |
US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
US20030225067A1 (en) * | 1999-06-04 | 2003-12-04 | Ruediger Stendel | Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs |
US6429224B1 (en) | 1999-12-06 | 2002-08-06 | Rhode Island Hospital, A Lifespan Partner | Use of taurolidine to treat tumors |
CN100519525C (zh) * | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
EP1797884B1 (de) * | 1999-12-06 | 2013-09-11 | Geistlich Pharma AG | Taurolidin oder Taurultam zur Verwendung bei der Behandlung von Tumoren der Prostata, des Kolons, der Lungen und von wiederkehrendem Glioblastoma multiforme. |
CA2363973C (en) * | 2000-11-28 | 2009-03-10 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
CA2441016A1 (en) * | 2001-03-15 | 2002-09-26 | Paul Calabresi | Taurine compounds |
EP1450814B1 (de) | 2001-10-01 | 2016-11-30 | Geistlich Pharma AG | Verfahren zur hemmung von metastasen |
JP2003119136A (ja) * | 2001-10-10 | 2003-04-23 | Mutsuyuki Kochi | 悪性細胞の分化誘導剤組成物とその使用 |
JP5346148B2 (ja) * | 2003-03-28 | 2013-11-20 | エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー | 抗新生物性組成物および治療方法 |
US8236794B2 (en) | 2003-09-29 | 2012-08-07 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
JP2007537200A (ja) * | 2004-05-14 | 2007-12-20 | ハンス−ディートリヒ・ポラシェグ | タウロリジン製剤及び投与:細菌マイクロフィルム形成に対する治療処置及び抗菌保護 |
WO2007019065A2 (en) * | 2005-08-04 | 2007-02-15 | Oklahoma Medical Research Foundation | Adjuvant chemotherapy for anaplastic gliomas |
US20100040667A1 (en) * | 2006-09-07 | 2010-02-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treating bone cancer |
US20170196875A1 (en) * | 2016-01-11 | 2017-07-13 | Cormedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
US20190381060A1 (en) * | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
US11541061B2 (en) | 2016-01-11 | 2023-01-03 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
CN105943522B (zh) * | 2016-05-19 | 2019-06-21 | 中国医学科学院基础医学研究所 | 氯福克酚用于制备治疗人神经胶质瘤的药物的用途 |
KR101880015B1 (ko) * | 2017-12-08 | 2018-07-19 | 아주대학교산학협력단 | 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물 |
US11738120B1 (en) | 2022-04-14 | 2023-08-29 | Cormedix Inc. | Synthesis of taurolidine, purity profiles and polymorphs |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8328111D0 (en) | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
US5210083A (en) * | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
GB9015108D0 (en) | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
US5416091A (en) * | 1990-12-18 | 1995-05-16 | Burroughs Wellcome Co. | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
JP3580867B2 (ja) * | 1994-09-07 | 2004-10-27 | 株式会社東芝 | 医療用ゾンデ |
GB9600426D0 (en) * | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
EP0981761A1 (de) * | 1997-05-15 | 2000-03-01 | Regents Of The University Of Minnesota | Schaltkreis mit einer Einheit zum Testen von Verbindungenvon Bilderzeugungdurch magnetische Resonanz zur gezielten Medikamentenabgabe an einen lebenden Patienten |
GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
US6479481B1 (en) | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
CA2302720C (en) | 1999-03-29 | 2009-07-14 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Anticoagulant/sterilizing compositions and methods |
US20020098164A1 (en) * | 2000-10-27 | 2002-07-25 | Redmond H. Paul | Treatment of tumor metastases and cancer |
US6429224B1 (en) * | 1999-12-06 | 2002-08-06 | Rhode Island Hospital, A Lifespan Partner | Use of taurolidine to treat tumors |
-
2000
- 2000-06-01 US US09/583,902 patent/US6479481B1/en not_active Expired - Lifetime
- 2000-06-02 CA CA2310534A patent/CA2310534C/en not_active Expired - Fee Related
- 2000-06-05 EP EP05017803.7A patent/EP1595543B1/de not_active Expired - Lifetime
- 2000-06-05 DE DE60024360T patent/DE60024360T2/de not_active Expired - Lifetime
- 2000-06-05 AT AT00304737T patent/ATE311179T1/de active
- 2000-06-05 ES ES00304737T patent/ES2251939T3/es not_active Expired - Lifetime
- 2000-06-05 JP JP2000168053A patent/JP2001010976A/ja active Pending
- 2000-06-05 ES ES05017803.7T patent/ES2532259T3/es not_active Expired - Lifetime
- 2000-06-05 EP EP00304737A patent/EP1066830B1/de not_active Expired - Lifetime
-
2002
- 2002-10-28 US US10/281,138 patent/US6815441B2/en not_active Expired - Lifetime
-
2003
- 2003-04-28 US US10/424,102 patent/US7638511B2/en not_active Expired - Fee Related
-
2008
- 2008-03-13 JP JP2008064507A patent/JP2008195726A/ja active Pending
-
2009
- 2009-10-29 US US12/608,748 patent/US8202860B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1595543A3 (de) | 2006-08-02 |
ES2251939T3 (es) | 2006-05-16 |
ES2532259T3 (es) | 2015-03-25 |
JP2008195726A (ja) | 2008-08-28 |
US20030064942A1 (en) | 2003-04-03 |
CA2310534A1 (en) | 2000-12-04 |
US20100048542A1 (en) | 2010-02-25 |
ATE311179T1 (de) | 2005-12-15 |
US20030195198A1 (en) | 2003-10-16 |
EP1595543B1 (de) | 2014-12-17 |
US7638511B2 (en) | 2009-12-29 |
US8202860B2 (en) | 2012-06-19 |
US6479481B1 (en) | 2002-11-12 |
US6815441B2 (en) | 2004-11-09 |
DE60024360T2 (de) | 2006-06-08 |
EP1066830A2 (de) | 2001-01-10 |
EP1066830B1 (de) | 2005-11-30 |
EP1595543A2 (de) | 2005-11-16 |
EP1066830A3 (de) | 2002-10-16 |
CA2310534C (en) | 2011-01-18 |
JP2001010976A (ja) | 2001-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60024360D1 (de) | Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS) | |
DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
CY1105460T1 (el) | Παραγωγα ακετυλενιου που εχουν mlgur 5 ανταγωνιστικη δραση | |
BR9811482A (pt) | Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico | |
PL342078A1 (en) | Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas | |
ATE412642T1 (de) | Inhibitoren von p-38-kinase | |
HK1026691A1 (en) | Substituted benzimidazoles and their use for treating retroviral infection | |
HK1042251A1 (en) | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | |
DE60027913D1 (de) | 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz | |
ATE227277T1 (de) | Isoxazoline derivate und ihre verwendung als antimikroben | |
DE60014136D1 (de) | Sapogenin derivate zur behandlung von kognitiven störungen | |
ATE251624T1 (de) | Granulatimide-derivate zur behandlung von krebs | |
DE69307674T2 (de) | HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS | |
MX9604762A (es) | Nuevas sulfonamidas y procedimiento para su preparacion. | |
ATE352307T1 (de) | Zusammensetzung zur behandlung von tumoren oder krebs, welche fluorouracil und ein methylol übertragungsmittel enthält | |
ID25478A (id) | Agonis 5-ht1f | |
ATE267018T1 (de) | Verwendung von peptidverbindungen zur behandlung von sle | |
ES2135383T3 (es) | Pirido(3,4-b)pirrolo(1,2-e)(1,4,5)oxadiazepinas y compuestos analogos relacionados, un procedimiento para su preparacion y su uso como medicamentos. | |
DE69827706D1 (de) | 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems | |
BG105549A (en) | Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system | |
DE60111571D1 (de) | Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität | |
EA200200656A1 (ru) | НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ | |
ES2072334T3 (es) | Derivados de 4,5,5a,6-tetrahidro-3h-isoxazolo(5,4,3-kl)acridinas, un procedimiento para su preparacion y su uso como medicamentos. | |
DE69503635T2 (de) | Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |